MEDI-493 data

MEDI released results of its double-blind, placebo-controlled, dose-escalating, multi-center Phase I/II trial of MEDI-493 to prevent RSV disease in

Read the full 196 word article

How to gain access

Continue reading with a
two-week free trial.